Cargando…
OR26-1 Alternative Polyadenylation as a Therapeutic Vulnerability in Prostate Cancer
Prostate cancer is the second leading cause of male cancer death in the United States. While localized disease can be cured by radiation or surgery, metastatic prostate cancer presents a clinical challenge. Metastatic prostate cancer can initially be controlled by endocrine therapies that target the...
Autores principales: | Dehm, Scott, Miller, Jeffery, Munro, Sarah, Van Etten, Jamie, Tietz, Kiel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625385/ http://dx.doi.org/10.1210/jendso/bvac150.1494 |
Ejemplares similares
-
OR26-5 Musashi-2 Regulatory Interactions Promote Adrenal Steroidogenesis
por: Baldwin, Amber, et al.
Publicado: (2022) -
SUN-LB002 CYP11A1 Inhibition as a Therapeutic Approach for the Treatment of Castration Resistant Prostate Cancer
por: Oksala, Riikka, et al.
Publicado: (2019) -
OR26-5 Functional Analysis of Estrogen-Regulated Enhancer RNAs in Breast Cancer Cells
por: Hou, Tim, et al.
Publicado: (2019) -
OR26-6 Glucocorticoid Receptor Quaternary Structure Drives Chromatin Occupancy and Transcriptional Outcome
por: Paakinaho, Ville, et al.
Publicado: (2019) -
OR26-2 mTOR Interacts with the Mineralocorticoid Receptor to Regulate its Activation by Ligand
por: Gomez-Sanchez, Celso E, et al.
Publicado: (2022)